LAST UPDATED
September 30, 2025
Clinicaltrials.gov ID
CTSID
OVERVIEW
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
PROTOCOL SUMMARY
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
View moreParticipation requirements
Age
18 years +
Sex
All
Healthy Volunteers
No
Age
18 years +
Sex
All
Healthy Volunteers
No
Study details
Medical Condition
Metastatic Solid Tumors
Gender
N/A
Date
August 2020 - October 2024
Study Type
Interventional
Study Phase
Phase 4
Product
Sacituzumab Govitecan-hiy
Eligibility information
Inclusion criteria
- Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study.
- Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy.
Exclusion criteria
- Females who are pregnant or lactating.
- Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated.
- Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy.
- Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Locations
Locations (21)
University of California San Francisco
San Francisco, California, United States, 94143
Christiana Care Health Services, Christiana Hospital
Newark, Delaware, United States, 19718
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, United States, 33905
Baptist Health - Miami Cancer Institute
Miami, Florida, United States, 33176
Illinois Cancer Specialists
Arlington Heights, Illinois, United States, 60005
University of MD Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States, 21201
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
New York Cancer & Blood Specialists - Setauket Medical Oncology
Port Jefferson, New York, United States, 11776
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15213
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.
Share Trial